Shanda wit sits on "Yi can new" main business to infant health care products concentration

From "Yiguoduan" to single-minded, Shanda wit (000915, closing price of 20.07 Yuan) has developed into a medicine-oriented, environmental protection and other industries as a supplement, specializing in child health drugs listed companies, and its largest product "Yi can be new" is the infant Industry "gold medicine", which may become the company's performance Take-off "wings."　　From diversity to focus on 2001, Shanda Wit, through a series of epitaxial expansion, in 2003 to 2006, including environmental protection, medicine, crystal materials, communications electronics and other fields, while relying on the advantages of low base, so that net profit has maintained a good growth trend. However, it is because the business is too complex, no real meaning of the main industry, Shanda wit some industries in recent years has encountered bottlenecks, greatly affecting the continued growth of performance. In the 2008 global financial crisis, its sales revenue composite growth rate of less than 5%. In order to break the dilemma of sluggish performance, Shanda wit began to reposition, the pharmaceutical industry to adjust to the leading industry.　　This has proved a new dawn for the company's development. In 2009 years, Shanda Wit realize the operating income of 499 million yuan, achieve net profit of 34.41 million yuan.　　The reason why there is such a good performance, relying on drug revenue, the business in the entire 2009 to contribute business income of 327 million yuan, operating profit of 281 million yuan, gross margin of up to 86.03%.　　The "Palm Treasure" "The Daily economic news" reporter learned that to help the company's drug business to take off, is its shareholding of 52.08% of Shandong Province, the Sea Life Pharmaceutical Co. Data show that after the acquisition of Shanda Wit 2003, the price of bio-sales composite growth reached 23%, net profit compound growth rate of 36%. At present, the Diane Biological rely on the hospital terminal market maintenance, to prescription-driven OTC sales, accumulated a greater advantage.　　In view of the capacity problem, the company began construction of new plant in 2008, the first phase of the project has been completed at the end of last year, production capacity will be increased by twice times, in the past the new dosage forms trapped in production will be gradually put into production. Industry insiders believe that there are two major products, the first is Iraq can be new, infant health care products, the absolute faucet, the second is to cover flute hin, performance growth faster.　　Among them, compared with similar products, Yi Kexin in the domestic market share ahead.　　2009, the operation income of the life of the 322 million yuan, net profit income of up to 137 million yuan, the parent company's contribution to profit of about 71.09 million yuan.　　Infant consumption space only depends on the infant health care products, can let Shanda wit achievement leap?　　The answer is yes. Huatai Joint analysis that the next 5 years, 1980-1990 years of "Baby Tide" will enter the marriage and childbirth phase, China will usher in the fourth "Baby Tide", and 0~4岁 infant consumption scale will be more than trillion yuan. At present, the prevalence rate of 0~4岁 children is comparable to those over 45 years of age, children's drug sales in the next 5 years will maintain double-digit growth, 2015 will reach 66.893 billion yuan, so optimistic about child health care products. The brokerage also said that according to the Chinese Health Association statistics, China's health care products market since 2006 has been an explosive growth situation, 2009 sales amounted to 13.4 billion U.S. dollars, nearly 4-year compound growth rate of 22.76%, has leapt to the world's second.　　and children's health products market occupies 1/4 of the market share of health care products. According to the "China Quality Miles" 2010, the second phase of "China Baby market Quality reputation Survey Report" shows that in the field of infant nutrition, the current market share of the top three in order to be the new 25.4%, three sperm 8.4%, dragon strong Bones 6.6%.　　This shows that Iraq can be a new leading position no one can shake. Guotai also believes that Yi Kexin has been in the domestic market for 9 consecutive years to maintain the city accounted for the first, with a brand advantage, product cost-effective than competitors have a clear advantage.　　With the launch of new capacity, the new will maintain more than 25% of the growth rate.　　Asset adjustment or performance surge Shanda Wit said in its 2010 business plan that the company would innovate and adjust its asset structure. Earlier this year, Shanda Wit issued an announcement that the 78.17% stake in the Wolong school was to be transferred to the Yinan County City state-owned Assets Operation Co., Ltd., taking the first step of focusing on the main business; in July, Shanda wit and Jinan huasheng Tiancheng Industrial Co., Ltd. signed the "Equity transfer Agreement",　　The company will hold Shan Dongshan da Kang Connaught Pharmaceutical Co., Ltd. 's 90% stake to 20.367 million yuan all the transfer to Jinan Hua Tiancheng. Shanda Wit Dong Fan Zhisheng in the daily economic news reporter interview, said, "the company in the restructuring of the asset structure, before planning out, inconvenient to disclose." "Citic Securities latest research, said that the current Shanda wit share price only reflects the value of the price of the stock, safety margin, coupled with the company's environmental business connotation changes, the prospect of time, the company expects earnings per share this year will reach 0.47 Yuan."